INTRODUCTION

Nocturnal enuresis (NE) is defined as the involuntary urination during sleep. Commonly known as bed-wetting, nocturnal enuresis occurs in night at bed during sleep WHO guidelines consider NE to be a pathological disorder if it persists after five years of age. NE causes significant inconvenience to the children and their parents. The prevalence of NE, varies according to age group and decreases as age advances, it is 15-20% at the age of 5, 5% at the age of 10, 1-2% at the age of 15 years. The primary etiology of NE is still
unknown; however, the decrease in the capacity of the urinary bladder increase urine production and deep sleep are the possible explanation.\(^1\)

The mode of inheritance of the disease is autosomal dominant with 90% penetrance, which means that the children of one parent suffering from NE have 40% chance of developing the disorder and if both parents have suffered from enuresis then this percentage is raised up to 70%. The genes related to this disorder are located on chromosomes 8, 12, 13, and 22.\(^2\) Furthermore, the patients of NE do not have neurological disorders, congenital or acquired; rather the change in the capacity of bladder and formation of urine during the night appear to be the primary reason of the condition.\(^3\)

Primary nocturnal enuresis (PNE) is when a child continues to have involuntary micturition in bed without ever having developed continence. If, it occurs after a child has achieved urinary continence, it is called secondary nocturnal enuresis (SNE). Therefore, it is essential to exclude secondary causes. A through history, examination and urine analysis as well u/s KUB are mandatory to exclude urinary tract infection diabetes, neurogenic bladder and VUR.\(^4\)

Treatment plans can be suggested in children above six years of age as the disorder is inconvenient. Usual management plans would include both medicine and also behavioral therapy. Sometimes, the management would comprise of multiple treatment modalities. If mono-therapy has proved to be ineffective then it is advisable to start combined therapies which are proven to be more effective. These therapies might contain one-to-one counseling, positive reinforcement and alarm.\(^5\) However, such treatment plans must be tailored case-by-case keeping in mind the needs of the child and the resources corresponding to the family’s affordance.\(^6\)

It is also important to differentiate between primary and secondary nocturnal enuresis since in the latter case, the disorder can often be managed by treating the secondary cause.\(^7\) The secondary causes of NE include diabetes insipidus, diabetes mellitus, constipation, intestinal blockage, urinary tract infection, seizures, neurogenic bladder or side effects of medication.

To begin the treatment, first a comprehensive history is taken and a thorough physical examination is performed. The points to be kept in mind while taking the history are: pattern of micturition i.e. urinary frequency during day and night, incontinence during the day, and a nocturnal enuresis frequency during one week, amount of water consumed during the day, evening and before sleeping should be documented as well. After that, general physical examination is conducted. This should always include close genital examination and special neurological examination.

Among the tests recommended generally are 1) Urinalysis for urinary tract infection or glycosuria, 2) Urinary system sonography, and 3) Residual Urine measurement post-voiding. Post-void volume helps in determining the urinary bladder function. Once the diagnosis of NE has been established, method of therapy is chosen.

Buzzer alarm, behavioral modification, and medicinal treatment, are the major methods of therapy for bed-wetting. The drugs used for treatment are the ADH-analog, desmopressin, Tricyclic antidepressants (TCAs), and anticholinergic drugs, like oxybutynin.\(^8\) The drug of choice for PNE is considered to be desmopressin which is available in the form of pills and nasal spray. The oral route of administration is preferred as it has faster onset of action and fewer side effects. Recommended dose of desmopressin is 20µg daily (for nasal inhalation) or 0.2 mg (for oral route).\(^9\) Recommendations suggest desmopressin treatment to continue for 3 months. If the patient fails to improve then the disorder is called desmopressin resistant nocturnal enuresis, which occurs in 20% of cases.\(^10\)

Unfortunately, no study predicting the use of desmopressin for nocturnal enuresis has been performed in our country. Our study is the first major study with a large sample size to validate the results of previous studies in our population. This will help clinicians in making informed choice about the management plan and increase awareness about the safety and efficacy of desmopressin and oxybutynin in our country. Therefore, the objective of our study was to evaluate the safety and efficacy of desmopressin monotherapy and its comparison with combination therapy with oxybutynin.

**METHODS**

This study was randomized controlled trial and convenient sampling technique was used to select the sample. The study was conducted at Bahria University Medical & Dental College (PNS Shifa Hospital) and the National Institute of Child Health, Karachi from September 2018 to March 2019 after obtaining ethical approval from the Ethical Review Committee (IERB No: 16/2017).
Data was collected from a sample size of 84 children after taking informed consent in writing from the parents and/or any other guardian of each child, ensuring thorough confidentiality. Eighty Four patients were divided into two groups of 42 children each labeled as Group-I and Group-II. Group-I comprised of children on desmopressin therapy alone and Group-II comprised of children receiving a combination therapy of desmopressin and oxybutynin. The required sample size in each Group-I.e. n1=42, n2=42, total= 84 was calculated using the software G POWER 3.1.9.2 with two portions; desmopressin monotherapy = 72.4% and desmopressin + oxybutynin = 83.3% taken from the study. The efficacy of desmopressin and oxybutynin combination therapy in children with nocturnal enuresis was compared via a randomized clinical trial using confidence interval for mean at 95% while keeping a 5% margin of error. Patients of either gender between the age group of 7 to 13 years who were diagnosed cases of nocturnal enuresis on the basis of clinical findings and history were included in the study. Patients with congenital anomalies, seizures and abnormalities of the central nervous system, diabetes insipidus, urinary tract infections or with a history of any other co morbids were excluded from the study. Subjects who were non-compliant or unable to follow up through the complete study period and patients whose parents/guardians did not consent for inclusion were also excluded.

Group-I comprised of patients on desmopressin monotherapy where a daily dosage of 0.2mg of desmopressin was given once daily for 90 days. Group-II had patients on combination therapy of desmopressin (0.2mg OD) orally + oxybutynin (5mg OD for 90 days). Double blinding of the study was done with neither the patients nor the doctors being aware of the patients on drug monotherapy or combination therapy. Patients were examined on the first visit and diagnosed on the basis of their history. Each patient was followed at the end of 1st, 2nd and 3rd month. After recording the demographic variables, the primary outcome was observed in terms of partial recovery, complete recovery and no recovery. Then, the patients were categorized into mild (once per week), moderate (two times per week) and severe (one time daily) nocturnal enuresis The safety of the drug and its combination therapy was assessed as the occurrence or absence of various side effects observed by the patient during the study period which included headache, nausea, vomiting, confusion, weakness, weight gain and/or loss of appetite.

Sample Size & Statistical Analysis: Sample size was calculated by two proportion method. n=P1-P2/Square root [{P1(1-P1)/n1} + {P2(1-P2)/n2}]. SPSS software version 20.0 was used to statistically analyze the data. Qualitative data was expressed as frequency and percentage and quantitative data was stated as mean and standard deviation, with independent t-test being used to calculate the mean difference. Chi-square test was applied to assess the association with p-value of <0.05 as the significant level.

RESULTS

Sample size was kept at a total of 84 children with 42 children in each group. In a total of 84 patients divided into two groups, the mean age of the patients was observed to be 9.30±1.89 years in Group-I and 8.57±2.24 years in Group-II with insignificant difference (p=0.250). Mean weight of the patients with a significant difference (p=0.010) was observed with 22.80±7.33 kg in Group-I and 21.28±4.53 kg in Group-II. Both the groups had similar educational status - 97.6% with primary level of education and 2.4% with middle. Insignificant association was observed in the socioeconomic class between the two groups (p=0.359). 11.9% of the patients in Group-I presented with a family history of hypertension whereas 4.8% of the patients in Group-II with insignificant association (p=0.236). 2.4% of the patients in Group-I and 4.8% of the patients in Group-II with insignificant association (p=0.557) had a family history of diabetes. Both the
groups had monosymptomatic type of nocturnal enuresis. 7.1% of the patients in Group-I and 2.4% of the patients in Group-II had a family history of nocturnal enuresis on the maternal side with insignificant association (p=0.306). Only 2.4% of the cases in both the groups had a family history of nocturnal enuresis on the paternal side. 61.9% of the patients in Group-I and 69.0% in Group-II patients with insignificant association (p=0.491) had siblings with a history of nocturnal enuresis. None of the cases from either of the groups presented with complain of day time wetting and/or irregularities in bowel habits.

7.1% of the patients showed severity of mild nature, 35.7% showed moderate and 57.1% exhibited extremely severity in Group-I. However, in Group-II, 2.4% of the patients were mild, 31.0% were moderate and 66.7% were severe with insignificant association (p=0.484). At the 4th week, in Group-I, 13(31.0%) showed complete recovery, 27(64.32%) showed partial recovery and two (4.8%) showed no recovery. Similarly, 13(31.0%) showed complete, 29(69.0%) showed partial and 0 (0.0%) showed no recovery in Group-II with insignificant association between the groups (p=0.355). At the 8th week 28(66.7%)
Treatment of Nocturnal Enuresis

Table-III: Side effects of treatment in children of different groups.

| Variables | Group-I | Group-II | p-value |
|-----------|---------|----------|---------|
| **Side Effect** | n (%) | n (%) |         |
| Allergic Reaction | Yes | 7 (16.7%) | 0 (0.0%) | 0.006 |
| Nausea | Yes | 7 (16.7) | 1 (2.4%) | 0.026 |
| Loss of Appetite | Yes | 2 (4.8%) | 16 (38.1%) | <0.001 |
| Headache | Yes | 12 (28.6%) | 2 (4.8%) | 0.003 |
| No | 35 (83.3%) | 41 (97.6%) |         |

Group-I: Desmopressin,
Group-II: Desmopressin + oxybutynin,
P value: Significant- Allergic reaction, Nausea, Loss of appetite, Headache, Test: Chi-square.

patients showed complete and 14(33.3%) patients showed partial recovery in Group-I. Similarly, 33(78.6%) patients showed complete and 9 (21.4%) showed partial recovery in Group-II with insignificant association (p=0.221).

At the 12th week 36(85.7%) patients showed complete recovery, five (11.9%) patients showed partial and one (2.4%) showed no recovery in Group-I. Whereas complete recovery was observed in all the 42 cases (100.0%) in Group-II with significant association (p=0.040).

As far as the side effects were concerned, 7 (16.7%) patients in Group-I and 1(2.4%) in Group-II developed nausea with significant association (p=0.026). Loss of appetite was observed in 4.8% of the patients in Group-I and 38.1% in Group-II with significant association (p<0.001). 12 (28.6%) patients in Group-I and 2(4.8%) patients in Group-II complained of headache, with significant association (p=0.003). 16.7% patients in Group-I exhibited allergic reactions whereas none exhibited the same in Group-II with significant association (p=0.006). Vomiting, weight gain, confusion and/or weakness were not exhibited by any of the patients in both the groups.

**DISCUSSION**

The recommended management plans for nocturnal enuresis (NE) include behavioral therapy, alarm therapy, and drug therapy. The drugs recommended for management include desmopressin, anticholinergic drugs and tricyclic antidepressants. However, drug monotherapy has not proven to be particularly effective. Therefore, combination therapy with desmopressin is usually the treatment of choice.11 About 20% to 60% of patients have desmopressin resistant nocturnal enuresis. These patients have reduced bladder volume but higher urine osmolarity as compared to the patients who respond well to the desmopressin therapy. Dairy intake might increase the urine osmolarity therefore dairy intake should be restricted.3 Desmopressin resistant NE is also associated with irregular bowel habits, sleep disorders, and mental disorders. The resistance in patients with nocturnal enuresis might frequently correlate with the occurrence of irregular bowel habits, mental and sleep disorders. Therefore, appropriate management is necessary.12

A study to compare the efficacy of desmopressin monotherapy and desmopressin and oxybutynin combination therapy was performed on 59 children aged 3 to 15. After a month of treatment, the success rate was 44.8% in monotherapy and 83.3% in combination therapy. These increased to 72% and 86.7% for monotherapy and combination therapy, respectively, after three months of treatment.13 Other studies comparing the efficacy of these therapies have also showed higher success rate for combination therapy.14,15 Our study also reported the similar results.

In another study, the recovery rate of monotherapy with desmopressin for three months in children aged 5 to 14 years was 82.5%.16 This is slightly lower than the 87% recovery rate observed in our study after 3 month of monotherapy.

A study of association of efficacy of desmopressin for NE with age and gender concluded that a significant association cannot be proved. An interesting finding was the higher recovery rate in children above seven years of age. Further research is suggested to prove these assertions.16 A study by Radvanska et al, concluded that monotherapy with desmopressin is less effective when compared to the combination therapy with oxybutynin. Combination therapy is helpful in cases which are desmopressin resistant.17 In another study with control group, consisting of desmopressin with placebo, and experimental group, given desmopressin with tolterodine, the combination therapy i.e. given to the experimental group, was found to be more effective.18 Our study also found higher efficacy of combination therapy.

Rombis et al conducted to compare the efficacy of combination therapy of desmopressin with oxybutynin with that of desmopressin with tolterodine. It concluded that the combination of desmopressin with tolterodine was much
more effective. However, our study showed the combination therapy of desmopressin with oxybutynin to be more effective.

In another study performed on 142 children with NE, the children were randomly assigned to three groups: Group-I treated with behavioral therapy, Group-II treated with desmopressin in combination with oxybutynin and Group-III treated with desmopressin in combination with toterodine. The results of this study are in line with our study in which the combination therapy of desmopressin with oxybutynin showed higher recovery rate. Similar studies have shown behavioral therapy alone to be less effective than pharmacological therapy. The effects of desmopressin on NE can be observed immediately but the effect is more pronounced after three weeks of treatment. Our study had similar results. The symptoms of the disease are relieved much more effectively by combination therapy than by monotherapy. However, the International Children’s Continence Society (ICCS) consider NE to be a relatively benign condition and recommends desmopressin monotherapy.

Martin et al. compared oxybutynin monotherapy with combination therapy of oxybutynin with desmopressin. They concluded that the combination therapy is much more effective than the monotherapy. Furthermore, the alleviation of symptoms is much higher in combination therapy as compared to monotherapy. This conclusion is also in concordance with the findings in our study.

The clinical trial conducted by Lee et al., presented a more complicated picture. It stated that while combination therapy has comparable cure rate as compared to the monotherapy, but the combination therapy requires much less time for cure. A randomized control trial was done to compare the efficacy of oxybutynin and desmopressin. It also found that the desmopressin monotherapy is more effective.

As regards side-effects, the common side effects of drug-therapy are dry mouth and constipation. The frequency of these side effects is slightly higher in combination therapy, but the difference is insignificant. In our study, allergic reactions, nausea, and headache were the common side effect of monotherapy. However, loss of appetite was seen more in combination therapy. A study to assess the safety and efficacy of toterodine monotherapy for NE found that the side effect of diarrhea was observed in 13% of the patients. Our study did not find any gastrointestinal side effects either in monotherapy or combination therapy. In our study, the most common side effects were headache for monotherapy, and loss of appetite for combination therapy. However, our study might not be free from reporting and observer bias.

**Limitations of the study:** It is an experimental study. The findings of this study suggestive of associations of effectiveness of monotherapy and combination therapy might not be immune from observer and reporting bias.

**CONCLUSION**

Complete response /recovery was achieved with combination therapy in all children (100%) where as it was 85.7% in children who received desmopressin as monotherapy for 12 weeks. Our study showed that the combination therapy of desmopressin with oxybutynin is more effective as compared to desmopressin alone. However, loss of appetite was common with combination therapy and headache was commonly observed with monotherapy. There were insignificant side effects observed in either group. However, appetite was observed in combination group.

**Recommendations:** Studies with longer follow ups and multiple observers who could take the multiple readings would be useful to reduce the bias in future studies and help in generalization of result.

**Acknowledgements:** Authors are highly grateful to all study participants.

**Conflict of interest:** None.

**Grant Support & Financial Disclosures:** None.

**REFERENCES**

1. Neveus T. Pathogenesis of enuresis: Towards a new understanding. Int J Urol. 2017;24(3):174-182. doi: 10.1111/iju.13310
2. Ravanshad Y, Azarfar A, Ghalegolab-Behbahan A, Mortazavi F, Ahmazadeh S, Ghofar F, et al. Comparing the efficacy of desmopressin and oxybutynin combination therapy and desmopressin in monotherapy in children with primary nocturnal enuresis; a randomized clinical trial. J Renal Inj Prev. 2017;6(4):259-263. doi: 10.15171/jrip.2017.49
3. Van Herzelee C, Evans J, Eggert P, Lottmann H, Norgaard JP, Vandewalle J. Predictive parameters of response to desmopressin in primary nocturnal enuresis. J Pediatr Urol. 2015;11(4):200.e1-8. doi: 10.1016/j.purol.2015.03.007
4. Ozden C, Ozdal OL, Altinova S, Oguzulgen I, Urgancioglu G, Memis A. Prevalence and associated factors of enuresis in Turkish children. Int Braz J Urol. 2007;33(2):216-222.
Treatement of Nocturnal Enuresis

5. Noh Y-H, Kim K-B. Recent Research on Treatments of Childhood Nocturnal Enuresis: Within Acupuncture, Moxbustion, Psychotherapy and Chiropractic. J Pediat Korean Med. 2011;25(3):1-11. doi: 10.7778/jpkm.2011.25.3.001

6. Basra RK, Wagg A, Chapple C, Cardozo L, Castro-Diaz D, Pons ME, et al. A review of adherence to drug therapy in patients with overactive bladder. BJU Int. 2008;102(7):774-779.

7. Akil IO, Ozmen D, Cetinkaya AC. Prevalence of urinary incontinence and lower urinary tract symptoms in school-age children. Urol J. 2014;11(3):1602-1608.

8. Neveus T. Pathogenesis of enuresis: Towards a new understanding. Int J Urol. 2017;24(3):174-182. doi: 10.1111/iju.13310

9. Ghasemi K, Esteghamati M, Mohammadzadeh M, Zare S. Desmopressin versus Oxybutynin for Nocturnal Enuresis in Children in Bandar Abbas: A Randomized Clinical Trial. Electronic Physician. 2016;8(3):2187-2193. doi: 10.19082/2187.

10. Walle JV, Rittig S, Bauer S, Eggert P, Marschall-Kehrel D, Tekgul S. Practical consensus guidelines for the management of enuresis. Eur J Pediatr. 2012;171(6):971-983. doi: 10.1007/s00431-012-1687-7

11. Kelm H. Enuresis in Children. Brazil J Urol. 2002;28(3):232-249.

12. Dossche L, Walle JV, VanHerzeele C. The pathophysiology of monosymptomatic nocturnal enuresis with special emphasis on the circadian rhythm of renal physiology. Eur J Pediatr. 2016;175(6):747-754.

13. Ravanshad Y, Azarfar A, Ghaleglobabehbahan A, Mortazavi F, Ahmadzadeh S, Ghforat F, et al. Comparing the efficacy of desmopressin and oxybutynin combination therapy and desmopressin monotherapy in children with primary nocturnal enuresis: A randomized clinical trial. J Renal Inj Prev. 2017;6(4):259-263. doi: 10.15171/jrip.2017.49

14. Lee T, Suh H, Lee HJ, Lee JE. Comparison of effect of treatment of primary nocturnal enuresis with oxybutynin plus desmopressin or desmopressin alone or imipramine alone: Are randomized controlled clinical trial. J Urol. 2005;174(3):1084-1087.

15. Kwak KW, Lee YS, Park KH, Baek M. Efficacy of desmopressin and enuresis alarm as first and second line treatment for primary monosymptomatic nocturnal enuresis: prospective randomized crossover study. J Urol. 2010;184(6):2521-2526.

16. Falak-ul-Afali B, Sharifi F, Torabi Z, Mozei F. Evaluation of Therapeutic effect of desmopressin on enuresis in children. J Zanjani Uni Med Sci Health Serv. 2007;15:11-16. doi: 10.1016/j.juro.2010.08.041

17. Radvanska E, Kovacs L, Rittig S. The role of bladder capacity in antiuretic and anticholinergic treatment for nocturnal enuresis. J Urol. 2006;176(2):764-768.

18. Austin PF, Ferguson G, Yan Y, Campigotto MJ, Royer ME, Coplen DE. Combination therapy with desmopressin and an anticholinergic medication for non responders to desmopressin form on symptomatic nocturnal enuresis: A randomized, double-blind, placebo-controlled trial. Pediatrics. 2008;122(5):1027-1032. doi: 10.1542/peds.2007-3691

19. Rombis V, Triantafyllidis A, Balaxis E, Kalaitzis C, Touloupidis S. Nocturnal enuresis in children. A four-year experience in outpatient clinics of pediatricurology. Folia Med (Plovdiv). 2005;47(2):24-28.

20. Reddy KR, Sripada R. Treatment and Management of Nocturnal Enuresis: A Review. International J Pharmaceut Clin Res. 2017;9(5):363-367. doi: 10.25288/ijPCR.v9i5.8959

21. Wille S. Comparison of Desmopressin and enuresis alarm for nocturnal enuresis. Arch Dis Child. 1986;61(1):30 33. doi: 10.1136/adc.61.1.30

22. Kaneko K. Treatment for nocturnal enuresis: The current state in Japan. Pediatr Int. 2012;54:8 13. doi: 10.1111/j.1442-200X.2011.03554.x

23. DiBianco JM, Morley C, Al Omar O. Nocturnal enuresis: A topic review and institution experience. Avicenna J Med. 2014;4:77 86. doi:10.4103/2221-0770.140641

24. Park SJ, Park JM, Pai KS, Ha TS, Lee SD, Baek M. Korean Children’s Continence and Enuresis Society. Desmopressin alone versus desmopressin and an anticholinergic in the first line treatment of primary monosymptomatic nocturnal enuresis: A multicenter study. Pediatr Nephrol. 2014;29(7):1195 1200. doi:10.1007/s00467-014-2751-5

25. Austin PF, Ferguson G, Yan Y, Campigotto MJ, Royer ME, Coplen DE. Combination therapy with desmopressin and an anticholinergic medication for non responders to desmopressin for monosymptomatic nocturnal enuresis: A randomized, double-blind, placebo-controlled trial. Pediatrics. 2008;122(5):1027-1032. doi:10.1542/peds.2007-3691

26. Martin-Crespo R, Luque R. In which patients is the oxybutynin-desmopressin combination therapy indicated? Cir Pediatr. 2003;16(4):181-185.

27. Munding M, Wessells H, Thornberry B, Rieden D. Use of tolterodine in children with dysfunctional voiding: An initial report. J Urol. 2002;165(3):926-928.

Authors’ Contribution:

AK: Principal investigator & Researcher, did data collection and manuscript writing, is responsible for integrity of research.

KNM: Clinical co-supervisor of the study, provided clinical expertise.

SZ: Performed ultrasound scan to rule out any abnormality in urinary bladder.

IHZ: Supervisor of the study. Conceived the idea and proof read the manuscript.

---

Authors:

1. Dr. Aziya Kazi, MBBS,
2. Prof. Dr. Khemchand N. Moorani, MBBS, MCPS, FCPs. Department of Paediatric Nephrology, National Institute of Child Health and Human Development (NICHD).
3. Dr. Shabih Zehra, MBBS, MCPS, FCPs. Department of Radiology, PNS Shifa Hospital DHA, Karachi, Pakistan.
4. Prof. Dr. Ijaz Hussain Zaidi Faisal, MBBS, PhD. 1,4: Pharmacology Department, Bahria University Medical & Dental College, Sailors Street, Adjacent PNS Shifa, Defence Phase 2, Karachi, Pakistan.